Voyager Therapeutics, Inc. (VYGR): Price and Financial Metrics


Voyager Therapeutics, Inc. (VYGR): $3.08

-0.08 (-2.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VYGR POWR Grades


  • VYGR scores best on the Value dimension, with a Value rank ahead of 95.79% of US stocks.
  • The strongest trend for VYGR is in Growth, which has been heading down over the past 31 weeks.
  • VYGR ranks lowest in Growth; there it ranks in the 1st percentile.

VYGR Stock Summary

  • With a price/earnings ratio of 2.99, Voyager Therapeutics Inc P/E ratio is greater than that of about merely 1.85% of stocks in our set with positive earnings.
  • The ratio of debt to operating expenses for Voyager Therapeutics Inc is higher than it is for about merely 0.49% of US stocks.
  • In terms of volatility of its share price, VYGR is more volatile than 89.84% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Voyager Therapeutics Inc, a group of peers worth examining would be MTEM, CRBP, JNCE, SGMO, and ZYME.
  • VYGR's SEC filings can be seen here. And to visit Voyager Therapeutics Inc's official web site, go to www.voyagertherapeutics.com.

VYGR Valuation Summary

  • In comparison to the median Healthcare stock, VYGR's price/sales ratio is 94.09% lower, now standing at 0.7.
  • VYGR's price/sales ratio has moved down 60.5 over the prior 69 months.
  • VYGR's price/earnings ratio has moved up 19.8 over the prior 69 months.

Below are key valuation metrics over time for VYGR.

Stock Date P/S P/B P/E EV/EBIT
VYGR 2021-06-28 1.0 1.2 4.2 1.2
VYGR 2020-12-01 1.6 1.8 7.7 4.0
VYGR 2018-10-05 49.1 6.6 -6.7 -6.0
VYGR 2018-02-02 82.2 5.9 -6.9 -6.2
VYGR 2017-05-09 22.2 2.0 -4.9 -3.9
VYGR 2016-08-10 24.0 2.5 -14.0 -12.7

VYGR Price Target

For more insight on analysts targets of VYGR, see our VYGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.61 Average Broker Recommendation 1.82 (Hold)

VYGR Stock Price Chart Interactive Chart >

Price chart for VYGR

VYGR Price/Volume Stats

Current price $3.08 52-week high $12.65
Prev. close $3.16 52-week low $3.04
Day low $3.04 Volume 204,165
Day high $3.17 Avg. volume 541,541
50-day MA $4.10 Dividend yield N/A
200-day MA $6.57 Market Cap 116.20M

Voyager Therapeutics, Inc. (VYGR) Company Bio


Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company was founded in 2013 and is based in Cambridge, Massachusetts.


VYGR Latest News Stream


Event/Time News Detail
Loading, please wait...

VYGR Latest Social Stream


Loading social stream, please wait...

View Full VYGR Social Stream

Latest VYGR News From Around the Web

Below are the latest news stories about Voyager Therapeutics Inc that investors may wish to consider to help them evaluate VYGR as an investment opportunity.

Is Weakness In Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

It is hard to get excited after looking at Voyager Therapeutics' (NASDAQ:VYGR) recent performance, when its stock has...

Yahoo | June 30, 2021

Voyager Therapeutics: Return On Capital Employed Insights

In Q1, Voyager Therapeutics (NASDAQ: VYGR ) posted sales of $6.50 million. Earnings were up 7.84%, but Voyager Therapeutics still reported an overall loss of $25.59 million. In Q4, Voyager Therapeutics brought in $6.54 million in sales but lost $23.73 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is Full story available on Benzinga.com

Benzinga | June 8, 2021

Voyager CEO Resigns After Company Turns Back To Discovery-Stage

Voyager Therapeutics, Inc (NASDAQ: VYGR ) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The companys CMO and R&D chief, Omar Khwaja, also stepped down after two years at the biotech. Voyager said that Turenne would leave to pursue other opportunities, and Khwaja found a new opportunity in Europe. Accordingly, the company Full story available on Benzinga.com

Benzinga | May 20, 2021

Voyager Therapeutics CEO and CMO Resign as Company Undergoes Strategic Shift

Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinsons disease program.

BioSpace | May 19, 2021

Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntingtons disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation targeted AAV capsids

BioSpace | May 18, 2021

Read More 'VYGR' Stories Here

VYGR Price Returns

1-mo -29.20%
3-mo -39.01%
6-mo -59.95%
1-year -74.86%
3-year -83.31%
5-year -78.43%
YTD -56.92%
2020 -48.75%
2019 48.40%
2018 -43.37%
2017 30.30%
2016 -41.83%

Continue Researching VYGR

Here are a few links from around the web to help you further your research on Voyager Therapeutics Inc's stock as an investment opportunity:

Voyager Therapeutics Inc (VYGR) Stock Price | Nasdaq
Voyager Therapeutics Inc (VYGR) Stock Quote, History and News - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0296 seconds.